{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:58:18Z","timestamp":1780102698664,"version":"3.54.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of Chongqing, China","award":["CSTB2024NSCQ-MSX0021, CSTB2023NSCQMSX0216"],"award-info":[{"award-number":["CSTB2024NSCQ-MSX0021, CSTB2023NSCQMSX0216"]}]},{"name":"Natural Science Foundation of Chongqing, China","award":["CSTB2024NSCQ-MSX0021, CSTB2023NSCQMSX0216"],"award-info":[{"award-number":["CSTB2024NSCQ-MSX0021, CSTB2023NSCQMSX0216"]}]},{"name":"Young Doctoral Project of Xinqiao Hospital","award":["2022YQB005,2022YQB046"],"award-info":[{"award-number":["2022YQB005,2022YQB046"]}]},{"name":"Young Doctoral Project of Xinqiao Hospital","award":["2022YQB005,2022YQB046"],"award-info":[{"award-number":["2022YQB005,2022YQB046"]}]},{"name":"Project for Young and Middle-aged Medical Talents of Chongqing","award":["2024GDRC013"],"award-info":[{"award-number":["2024GDRC013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-95509-6","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T09:43:08Z","timestamp":1743846188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transcriptomic analysis of the anti-tumor effects of leflunomide in prolactinoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Xiangdong","family":"Pei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huachun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenle","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifeng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"95509_CR1","doi-asserted-by":"publisher","first-page":"103102","DOI":"10.1016\/j.arcmed.2024.103102","volume":"55","author":"F Haidenberg-David","year":"2024","unstructured":"Haidenberg-David, F. et al. Overview of hyperprolactinemia: general approach and reproductive health implications. Arch. Med. Res. 55, 103102 (2024).","journal-title":"Arch. Med. Res."},{"key":"95509_CR2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12020-023-03310-0","volume":"80","author":"H Tang","year":"2023","unstructured":"Tang, H. et al. Drd2 expression based on 18F-Fallypride Pet\/Mr predicts the dopamine agonist resistance of prolactinomas: A pilot study. Endocrine 80, 419\u2013424 (2023).","journal-title":"Endocrine"},{"key":"95509_CR3","doi-asserted-by":"publisher","first-page":"1018090","DOI":"10.3389\/fendo.2022.1018090","volume":"13","author":"A Glezer","year":"2022","unstructured":"Glezer, A., Santana, M. R., Bronstein, M. D., Donato, J. J. & Jallad, R. S. The interplay between prolactin and cardiovascular disease. Front. Endocrinol. 13, 1018090 (2022).","journal-title":"Front. Endocrinol."},{"key":"95509_CR4","doi-asserted-by":"publisher","first-page":"101887","DOI":"10.1016\/j.beem.2024.101887","volume":"38","author":"I Shimon","year":"2024","unstructured":"Shimon, I. Real-World value of Cabergoline in the treatment of acromegaly. Best Pract. Res. Clin. Endocrinol. Metab. 38, 101887 (2024).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"95509_CR5","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1111\/jcpt.13460","volume":"46","author":"MM Fachi","year":"2021","unstructured":"Fachi, M. M., de Deus Bueno, L., de Oliveira, D. C., da Silva, L. L. & Bonetti, A. F. Efficacy and safety in the treatment of hyperprolactinemia: A systematic review and network Meta-analysis. J. Clin. Pharm. Ther. 46, 1549\u20131556 (2021).","journal-title":"J. Clin. Pharm. Ther."},{"key":"95509_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000495775","volume":"109","author":"D Maiter","year":"2019","unstructured":"Maiter, D. Management of dopamine Agonist-Resistant prolactinoma. Neuroendocrinology 109, 42\u201350 (2019).","journal-title":"Neuroendocrinology"},{"key":"95509_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.17925\/EE.2022.18.2.86","volume":"18","author":"H Boharoon","year":"2022","unstructured":"Boharoon, H. & Grossman, A. A. New medical therapy for multiple endocrine neoplasia type 1? TouchREV Endocrinol. 18, 86\u201388 (2022).","journal-title":"TouchREV Endocrinol."},{"key":"95509_CR8","doi-asserted-by":"publisher","first-page":"218","DOI":"10.12998\/wjcc.v11.i1.218","volume":"11","author":"S Kim","year":"2023","unstructured":"Kim, S. et al. Pembrolizumab-Induced psoriatic arthritis treated with Disease-Modifying Anti-rheumatic drugs in a patient with gastric cancer: A case report. World J. Clin. Cases. 11, 218\u2013224 (2023).","journal-title":"World J. Clin. Cases"},{"key":"95509_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/genes14010089","volume":"14","author":"S Peretti","year":"2022","unstructured":"Peretti, S. et al. The Yin-Yang pharmacomicrobiomics on treatment response in inflammatory arthritides: A narrative review. Genes (Basel). 14, 89 (2022).","journal-title":"Genes (Basel)"},{"key":"95509_CR10","doi-asserted-by":"publisher","first-page":"232470962211506","DOI":"10.1177\/23247096221150636","volume":"11","author":"DM Salazar","year":"2023","unstructured":"Salazar, D. M. et al. Leflunomide-Induced Immune-Mediated necrotizing myopathy in a patient with rheumatoid arthritis: A case report. J. Investig Med. High. Impact Case Rep. 11, 23247096221150636 (2023).","journal-title":"J. Investig Med. High. Impact Case Rep."},{"key":"95509_CR11","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.21037\/atm-2022-62","volume":"10","author":"MP Castro","year":"2022","unstructured":"Castro, M. P. et al. Targeting chromosome 12Q amplification in relapsed glioblastoma: the use of computational biological modeling to identify effective therapy-A case report. Ann. Transl Med. 10, 1289 (2022).","journal-title":"Ann. Transl Med."},{"key":"95509_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1158\/1535-7163.MCT-08-0664","volume":"8","author":"P Baumann","year":"2009","unstructured":"Baumann, P. et al. Dihydroorotate dehydrogenase inhibitor a771726 (Leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol. Cancer Ther. 8, 366\u2013375 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"95509_CR13","doi-asserted-by":"publisher","first-page":"e71555","DOI":"10.1371\/journal.pone.0071555","volume":"8","author":"S Zhu","year":"2013","unstructured":"Zhu, S., Yan, X., Xiang, Z., Ding, H. F. & Cui, H. Leflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivo. Plos One. 8, e71555 (2013).","journal-title":"Plos One"},{"key":"95509_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1756-8722-3-26","volume":"3","author":"C Hwang","year":"2010","unstructured":"Hwang, C. & Heath, E. I. Angiogenesis inhibitors in the treatment of prostate cancer. J. Hematol. Oncol. 3, 26 (2010).","journal-title":"J. Hematol. Oncol."},{"key":"95509_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.lfs.2015.10.003","volume":"141","author":"HI Bahr","year":"2015","unstructured":"Bahr, H. I. et al. Chemopreventive effect of Leflunomide against Ehrlich\u2019s solid tumor grown in mice: effect on Egf and EGFR expression and tumor proliferation. Life Sci. 141, 193\u2013201 (2015).","journal-title":"Life Sci."},{"key":"95509_CR16","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.4161\/cc.6.24.5096","volume":"6","author":"FM Uckun","year":"2007","unstructured":"Uckun, F. M. Chemosensitizing Anti-cancer activity of Lfm-a13, a Leflunomide metabolite analog targeting Polo-Like kinases. Cell. Cycle. 6, 3021\u20133026 (2007).","journal-title":"Cell. Cycle"},{"key":"95509_CR17","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.neo.2014.08.006","volume":"16","author":"ME Doscas","year":"2014","unstructured":"Doscas, M. E. et al. Inhibition of P70 S6 kinase (S6K1) activity by a77 1726 and its effect on cell proliferation and cell cycle progress. Neoplasia 16, 824\u2013834 (2014).","journal-title":"Neoplasia"},{"key":"95509_CR18","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1136\/ard.2007.086264","volume":"68","author":"E Kis","year":"2009","unstructured":"Kis, E. et al. Leflunomide and its metabolite a771726 are high affinity substrates of Bcrp: implications for drug resistance. Ann. Rheum. Dis. 68, 1201\u20131207 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"95509_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/1078-0432.CCR-11-1049","volume":"18","author":"S Dietrich","year":"2012","unstructured":"Dietrich, S. et al. Leflunomide induces apoptosis in Fludarabine-Resistant and clinically refractory Cll cells. Clin. Cancer Res. 18, 417\u2013431 (2012).","journal-title":"Clin. Cancer Res."},{"key":"95509_CR20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jss.2013.05.089","volume":"185","author":"A Alhefdhi","year":"2013","unstructured":"Alhefdhi, A., Burke, J. F., Redlich, A., Kunnimalaiyaan, M. & Chen, H. Leflunomide suppresses growth in human medullary thyroid cancer cells. J. Surg. Res. 185, 212\u2013216 (2013).","journal-title":"J. Surg. Res."},{"key":"95509_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ejphar.2013.11.022","volume":"723","author":"M Nasr","year":"2014","unstructured":"Nasr, M., Selima, E., Hamed, O. & Kazem, A. Targeting different angiogenic pathways with combination of Curcumin, Leflunomide and Perindopril inhibits Diethylnitrosamine-Induced hepatocellular carcinoma in mice. Eur. J. Pharmacol. 723, 267\u2013275 (2014).","journal-title":"Eur. J. Pharmacol."},{"key":"95509_CR22","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1593\/neo.10168","volume":"12","author":"NJ Hail","year":"2010","unstructured":"Hailm N. J., Chen, P. & Bushman, L. R. Teriflunomide (Leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for Teriflunomide in prostate cancer chemoprevention. Neoplasia 12, 464\u2013475 (2010).","journal-title":"Neoplasia"},{"key":"95509_CR23","doi-asserted-by":"publisher","first-page":"e40926","DOI":"10.1371\/journal.pone.0040926","volume":"7","author":"EF O\u2019Donnell","year":"2012","unstructured":"O\u2019Donnell, E. F. et al. The Aryl hydrocarbon receptor mediates Leflunomide-Induced growth Inhibition of melanoma cells. Plos One. 7, e40926 (2012).","journal-title":"Plos One"},{"key":"95509_CR24","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/sj.leu.2404922","volume":"22","author":"I Ringshausen","year":"2008","unstructured":"Ringshausen, I., Oelsner, M., Bogner, C., Peschel, C. & Decker, T. The Immunomodulatory drug Leflunomide inhibits cell cycle progression of B-Cll cells. Leukemia 22, 635\u2013638 (2008).","journal-title":"Leukemia"},{"key":"95509_CR25","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nature09882","volume":"471","author":"RM White","year":"2011","unstructured":"White, R. M. et al. Dhodh modulates transcriptional elongation in the neural crest and melanoma. Nature 471, 518\u2013522 (2011).","journal-title":"Nature"},{"key":"95509_CR26","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s00280-004-0769-2","volume":"53","author":"PC Adamson","year":"2004","unstructured":"Adamson, P. C. et al. Pediatric phase I trial and Pharmacokinetic study of the Platelet-Derived growth factor (Pdgf) receptor pathway inhibitor Su101. Cancer Chemother. Pharmacol. 53, 482\u2013488 (2004).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"95509_CR27","first-page":"800","volume":"7","author":"YJ Ko","year":"2001","unstructured":"Ko, Y. J. et al. A Multi-institutional phase Ii study of Su101, a Platelet-Derived growth factor receptor inhibitor, for patients with Hormone-Refractory prostate cancer. Clin. Cancer Res. 7, 800\u2013805 (2001).","journal-title":"Clin. Cancer Res."},{"key":"95509_CR28","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1200\/JCO.1999.17.4.1095","volume":"17","author":"SG Eckhardt","year":"1999","unstructured":"Eckhardt, S. G. et al. Phase I and Pharmacologic study of the tyrosine kinase inhibitor Su101 in patients with advanced solid tumors. J. Clin. Oncol. 17, 1095\u20131104 (1999).","journal-title":"J. Clin. Oncol."},{"key":"95509_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.26502\/josm.511500060","volume":"4","author":"AL Alejo","year":"2022","unstructured":"Alejo, A. L. et al. A Pre-Clinical standard operating procedure for evaluating orthobiologics in an in vivo rat spinal fusion model. J. Orthop. Sports Med. 4, 224\u2013240 (2022).","journal-title":"J. Orthop. Sports Med."},{"key":"95509_CR30","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/j.1476-5381.2010.00873.x","volume":"160","author":"JC McGrath","year":"2010","unstructured":"McGrath, J. C., Drummond, G. B., McLachlan, E. M., Kilkenny, C. & Wainwright, C. L. Guidelines for reporting experiments involving animals: the arrive guidelines. Br. J. Pharmacol. 160, 1573\u20131576 (2010).","journal-title":"Br. J. Pharmacol."},{"key":"95509_CR31","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1080\/01652176.1986.9694068","volume":"8","author":"International Guiding Principles for Biomedical Research Involving Animals Issued by Cioms","year":"1986","unstructured":"International Guiding Principles for Biomedical Research Involving Animals Issued by Cioms. Vet. Q. 8, 350\u2013352 (1986).","journal-title":"Vet. Q."},{"key":"95509_CR32","doi-asserted-by":"crossref","unstructured":"Brown, M. J. et al. Cult. Care: Organizational Responsibilities 11\u201326 (2018).","DOI":"10.1201\/9781315152189-2"},{"key":"95509_CR33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1186\/1471-2105-11-485","volume":"11","author":"MP Cox","year":"2010","unstructured":"Cox, M. P., Peterson, D. A., Biggs, P. J. & Solexaqa At-a-Glance quality assessment of illumina Second-Generation sequencing data. BMC Bioinform. 11, 485 (2010).","journal-title":"BMC Bioinform."},{"key":"95509_CR34","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/bioinformatics\/btp120","volume":"25","author":"C Trapnell","year":"2009","unstructured":"Trapnell, C., Pachter, L. & Salzberg, S. L. Tophat: discovering splice junctions with Rna-Seq. Bioinformatics 25, 1105\u20131111 (2009).","journal-title":"Bioinformatics"},{"key":"95509_CR35","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nprot.2012.016","volume":"7","author":"C Trapnell","year":"2012","unstructured":"Trapnell, C. et al. Differential gene and transcript expression analysis of Rna-Seq experiments with tophat and cufflinks. Nat. Protoc. 7, 562\u2013578 (2012).","journal-title":"Nat. Protoc."},{"key":"95509_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J., Smyth, G. K. & Edger A bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"95509_CR37","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Metascape provides a Biologist-Oriented resource for the analysis of Systems-Level datasets. Nat. Commun. 10, 1523 (2019a).","journal-title":"Nat. Commun."},{"key":"95509_CR38","doi-asserted-by":"publisher","first-page":"W305","DOI":"10.1093\/nar\/gkp427","volume":"37","author":"J Chen","year":"2009","unstructured":"Chen, J., Bardes, E. E., Aronow, B. J. & Jegga, A. G. Toppgene suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 37, W305\u2013W311 (2009).","journal-title":"Nucleic Acids Res."},{"key":"95509_CR39","doi-asserted-by":"publisher","first-page":"W234","DOI":"10.1093\/nar\/gkz240","volume":"47","author":"G Zhou","year":"2019","unstructured":"Zhou, G. et al. Networkanalyst 3.0: A visual analytics platform for comprehensive gene expression profiling and Meta-analysis. Nucleic Acids Res. 47, W234\u2013W241 (2019b).","journal-title":"Nucleic Acids Res."},{"key":"95509_CR40","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.bbrc.2018.01.107","volume":"496","author":"C Zhang","year":"2018","unstructured":"Zhang, C., Chu, M. & Leflunomide A promising drug with good antitumor potential. Biochem. Biophys. Res. Commun. 496, 726\u2013730 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"95509_CR41","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2147\/DDDT.S252626","volume":"14","author":"L Cheng","year":"2020","unstructured":"Cheng, L. et al. Leflunomide inhibits proliferation and induces apoptosis via suppressing autophagy and Pi3K\/Akt signaling pathway in human bladder cancer cells. Drug Des. Dev. Ther. 14, 1897\u20131908 (2020).","journal-title":"Drug Des. Dev. Ther."},{"key":"95509_CR42","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/1535-7163.MCT-20-0567","volume":"20","author":"R Jin","year":"2021","unstructured":"Jin, R. et al. Leflunomide suppresses the growth of LKB1-Inactivated tumors in the Immune-Competent host and attenuates distant cancer metastasis. Mol. Cancer Ther. 20, 274\u2013283 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"95509_CR43","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.18632\/oncotarget.23378","volume":"9","author":"K Hanson","year":"2018","unstructured":"Hanson, K. et al. The Anti-Rheumatic drug, Leflunomide, synergizes with Mek Inhibition to suppress melanoma growth. Oncotarget 9, 3815\u20133829 (2018).","journal-title":"Oncotarget"},{"key":"95509_CR44","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.omto.2019.04.006","volume":"14","author":"R Buettner","year":"2019","unstructured":"Buettner, R. et al. Leflunomide synergizes with gemcitabine in growth Inhibition of Pc cells and impairs C-Myc signaling through Pim kinase targeting. Mol. Ther. -Oncolytics. 14, 149\u2013158 (2019).","journal-title":"Mol. Ther. -Oncolytics"},{"key":"95509_CR45","doi-asserted-by":"publisher","first-page":"110132","DOI":"10.1016\/j.isci.2024.110132","volume":"27","author":"T Mirzapoiazova","year":"2024","unstructured":"Mirzapoiazova, T. et al. Teriflunomide\/Leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via Drp1 in Sclc. Iscience 27, 110132 (2024).","journal-title":"Iscience"},{"key":"95509_CR46","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41419-022-04596-0","volume":"13","author":"Z Zhu","year":"2022","unstructured":"Zhu, Z. et al. Ube2T-Mediated Akt ubiquitination and Akt\/Beta-Catenin activation promotes hepatocellular carcinoma development by increasing pyrimidine metabolism. Cell. Death Dis. 13, 154 (2022).","journal-title":"Cell. Death Dis."},{"key":"95509_CR47","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1158\/2159-8290.CD-16-0611","volume":"7","author":"KK Brown","year":"2017","unstructured":"Brown, K. K., Spinelli, J. B., Asara, J. M. & Toker, A. Adaptive reprogramming of de Novo pyrimidine synthesis is a metabolic vulnerability in Triple-Negative breast cancer. Cancer Discov. 7, 391\u2013399 (2017).","journal-title":"Cancer Discov"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95509-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95509-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95509-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T20:05:15Z","timestamp":1743969915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95509-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95509"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-95509-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was reviewed and approved by the ethics committee of Army Medical University (AMUWEC20210074). All animal experiments were performed in accordance with the ARRIVE guidelines. All participants have signed informed consent forms.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"11703"}}